IOSP
Innospec Inc
$84.37
▲ 0.5%Updated Today 3:42 PM ET
IOSP at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
8.0%
Interest Coverage
34.08x
Current Ratio
2.98x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Innospec Inc (IOSP) is a small-cap company in the Chemicals industry, part of the Materials sector of the S&P 500.
In its latest reported year it generated about $1.78B in revenue.
Our model rates IOSP Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
29.1% average over the last 3 years
±2.6 pts around 30.4% across 10 years
grew in 5 of the last 9 year-over-year periods
positive in 10 of 10 years
8.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
4Y CAGR
4.6%
Revenue moved from $883.40M in 2016 to $1.78B in 2025, a 8.1% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
27.7%
Operating Margin
7.3%
Net Margin
—
ROE
—
Total Debt
$0.00
Net Debt
-$289.10M
Net cash position
Net Debt / EBITDA
-2.23x
Debt / Equity
—
Leverage: debt-to-equity is n/a, and operating profit covers interest about 34.1x, with a current ratio of 3.0x. Detailed balance-sheet leverage is limited for this name. It carries roughly $0.00 of total debt against $289.10M of cash.
Operating CF
$138.30M
Free Cash Flow
$88.00M
FCF Margin
4.9%
In the latest year Innospec Inc produced about $138.30M of operating cash flow and $88.00M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The payout is comfortably covered by cash the business actually generates, with a raise habit behind it.
Per share (latest FY)
$1.71
Total paid (latest FY)
$42.40M
History on record
10 years
dividend uses 48% of free cash flow
total dividends increased 9 years in a row
no cuts in the last 10 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
IOSP trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$61.34
Current price
$84.37
Starting FCF (latest 10-K)
$88.00M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where IOSP sits versus its Materials sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 54 Materials companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How IOSP stacks up against its Materials peers — valuation, profitability, and growth versus the sector median.
In the Materials sector (78 S&P 500 companies), IOSP ranks #65 of 78 by our overall rating.
P/E vs sector
—
median 21.5x
ROE vs sector
—
median 16.1%
Growth vs sector
—
median 7.9%
Sector rank
#65
of 78 by rating
Peers are the closest Materials companies by sub-industry and size. Sector median is across all 78 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $84.37 today · expected CAGR 9% – 20%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.92B | $2.07B | $2.24B | $2.42B | $2.61B |
| Net income | $192.02M | $207.39M | $223.98M | $241.89M | $261.25M |
| EPS | $7.80 | $8.42 | $9.09 | $9.82 | $10.61 |
| Share price (low) | $93.55 | $101.04 | $109.12 | $117.85 | $127.28 |
| Share price (high) | $155.92 | $168.39 | $181.87 | $196.41 | $212.13 |
| CAGR (low–high) | 11% / 85% | 9% / 41% | 9% / 29% | 9% / 24% | 9% / 20% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for IOSP:
- As an established S&P 500 member in Materials, it brings scale and a long operating history.
The case against IOSP:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Innospec Inc is a small-cap materials business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 9 Wall Street analysts covering IOSP recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
IOSP's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
IOSP — frequently asked questions
Is IOSP a good stock to buy?
We don't give buy or sell advice. Review Innospec Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does IOSP's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Innospec Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for IOSP calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this IOSP analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell IOSP. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.